BioSig says physicians have completed 1,000 patient cases with its PURE EP system technology across nine US installation sites

BioSig Technologies Inc (NASDAQ:BSGM) has announced that physicians have completed 1,000 patient cases with its technology across nine installation sites. The company’s non-invasive computerized technology, the PURE EP system, aims to drive procedural efficiency and efficacy in electrophysiology. The system provides essential diagnostic signals with high clinical value in all cardiac ablations that treat irregular heartbeats or arrhythmias. Previously, BioSig increased the patient case goal from 1,000 to at least 1,500 procedures by the end of 2021, having delivered 425 procedures at the end of 2020.  READ: BioSig Technologies to present data from a study of its PURE EP system at Heart Rhythm 2021 in July The company said it is currently conducting patient cases in nine medical centers across the country. Texas Cardiac Arrhythmia Institute at St. David’s Medical Center in Austin, Mayo Clinic Florida Campus — BioSig’s first commercial customers — and the University of Pennsylvania count among the most prominent technology users with over 600 patient cases conducted to date. “We are thrilled to cross the 1000-case milestone, a figure that was our initial target for the entire 2021,” said BioSig CEO Kenneth Londoner in a statement. “Most importantly, this case growth allows us to collect vast amounts of clinical data daily, providing us with immense intelligence that is vital for our clinical and commercial strategy. Increased technology usage in elective procedures is a much-awaited sign of the steady pandemic recovery in our country, and we are looking forward to a strong second half of 2021,”  The company said it is in the targeted commercial launch phase, focusing on expanding its clinical footprint across the Northeast, Texas, and Florida, the three regions that account for the largest electrophysiology programs in the country.  The company also recently expanded its commercial team by appointing Walt Quinn to lead regional sales in Florida. Quinn brings to the company over 25 years of medical device and capital equipment sales experience in some of the leading companies in the field, including Ethicon (a Johnson & Johnson company), Medtronic, Topera (an Abbott company), and CardioFocus. Meanwhile, BioSig said it will be exhibiting at the annual Heart Rhythm 2021 convention on July 28-31 at the Boston Convention and Exhibition Center. BioSig’s executive leadership, clinical, commercial, and engineering teams will host a series of presentations that will showcase the latest clinical data and demonstrate the newest software features of its PURE EP system. BioSig pointed out that one in 18 Americans suffers from cardiac arrhythmia. Atrial fibrillation is the most common arrhythmia type, affecting over 33 million people worldwide, including over 6 million in the US. According to the Centers for Disease Control and Prevention (CDC), atrial fibrillation causes more than 750,000 hospitalizations in the US each year, resulting in about $6 billion in healthcare spending annually. Contact the author: patrick@proactiveinvestors.com Follow him on Twitter @PatrickMGraham